• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Drug Self-Administration to 2022

  • ID: 3064212
  • January 2015
  • Region: Global
  • Greystone Associates
Indications, Markets, Players, Strategies and Forecasts

While alternative methods for delivering therapeutics to patients have had some notable successes, most drugs continue to be delivered orally. Because they cannot tolerate the first-pass metabolism of the digestive tract, the recent escalation in new biological drugs, including antibodies and recombinant proteins, is placing renewed emphasis on alternate delivery technologies. Now a number of factors are converging to create both risk and opportunity for drug makers and their delivery device partners. These include new classes of drugs for previously refractory conditions, the growing trend toward self-administration for chronic diseases, shifting patient demographics in industrial countries, caregiver safety legislation, and continued pressure to control healthcare costs. These factors are giving rise to a new generation of sophisticated, application-specific injection, inhalation and transdermal drug products designed to satisfy caregiver and patient preferences while addressing managed care initiatives and the formulation limitations of new classes of therapeutic drugs. Because of their ability to safely and reliably satisfy treatment protocols and compliance goals, non-oral drug READ MORE >

Note: Product cover images may vary from those shown
Indications, Markets, Players, Strategies and Forecasts

1. Executive Summary

2. Drug Market Dynamics
- Evolving Drug Development and Market Factors
- Managed Care and Prescribing Trends
- Drug Self-Administration Demand Factors
- Shifting Patient Demographics
- Chronic Disease and Self-administration
- Biological Drugs Proliferating
- Delivery Device Technology & Evolving

3. Injectable Drug Self-Administration
- Market Sector Dynamics
- Prefilled Syringes (PFS)
- Glass PFS
- Plastic PFS
- Autoinjectors
- Pen Injectors
- Reusable Pens
- Disposable Pens
- Needle-free Injectors (NFI)
- Competitive NFI Therapeutic Segments
- Needle-free Company Profiles

4. Inhaled Drug Self-Administration Products
- Market Sector Dynamics
- The Upper Respiratory Market
- The Systemic/Deep Lung Market
- Inhaler Technology and Market Prospects
- Inhaler Product Segments
- Dry Powder Inhalers
- Metered Dose Inhalers
- Nebulizers
- Performance Factors
- Bioavailability
- Dose Reproducibility
- Active Compound Stability

5. Transdermal Drug Products
- Market Sector Dynamics
- Prescription Patch Design & Technology
- Active Transport Patch Technologies
- Prescription Patch Development Factors
- Key Transdermal Therapeutic Markets
- Transdermal Product Company Profiles

6. Drug Self-Administration: Therapeutic Sector Analysis & Forecasts
- Anticoagulants
- Arthritis
- Asthma/COPD
- Cardiovascular
- Contraception
- Cystic Fibrosis
- Diabetes
- Hematopoietics
- Hepatitis
- Hormone Therapy/Replacement
- Multiple Sclerosis
- Neurology
- Osteoporosis
- Pain Management
- Psoriasis
- Sexual Health

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Bayer AG LEO Laboratories Ltd. Grünenthal GmbH Medtronic, Inc. Teva Pharmaceutical Industries Ltd. Pall Corporation